This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Review of Response to Therapy

Mark R. Rosenberg, MD; Marylee Green, MD

Arch Intern Med. 1989;149(9):1927-1931.

Abstract
• The purpose of this study was to evaluate options available for the treatment of neuroleptic malignant syndrome. We conducted a computer search of English-language literature using a Medline database and review of bibliographies of identified articles. Sixty-four case reports containing sufficient data about patients demographics and clinical response to therapy to allow evaluation were combined with three previously unreported cases. The mean time to clinical response was 6.8 days when supportive measures alone were used in the treatment of neuroleptic malignant syndrome. The addition of dantrolene (response time, 1.15 days) or bromocriptine (response time, 1.03 days) significantly shortened the time to clinical response. We conclude that the addition of either dantrolene or bromocriptine to conservative measures decreases the time to clinical response. A randomized trial would address potential case selection biases.

(Arch Intern Med. 1989;149:1927-1931)

Author Affiliations
From the Department of Medical Education, Providence Medical Center, Portland, Ore (Drs Rosenberg and Green), and the Department of Medicine, Oregon Health Sciences University, Portland (Dr Rosenberg).

Footnotes
Accepted for publication March 31, 1989.

Reprint requests to Providence Medical Center, 4805 NE Glisan St, Portland, OR 97213-2967 (Dr Rosenberg).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Neuroleptic Malignant Syndrome Complicating Antipsychotic Treatment of Delirium or Agitation in Medical and Surgical Patients: Case Reports and A Review of the Literature
Seitz and Gill
Psychosomatics 2009;50:8-15.
ABSTRACT | FULL TEXT  

Neuroleptic Malignant Syndrome
Strawn et al.
Am. J. Psychiatry 2007;164:870-876.
FULL TEXT  

Genetic Predisposition to Neuroleptic Malignant Syndrome in Siblings
Ziegenbein et al.
The Annals of Pharmacotherapy 2006;40:574-575.
FULL TEXT  

Acute Dystonic Reaction and the Neuroleptic Malignant Syndrome
White
Journal of Pharmacy Practice 2005;18:175-187.
ABSTRACT  

Neuroleptic malignant syndrome: case report and discussion
Chandran et al.
CMAJ 2003;169:439-442.
ABSTRACT | FULL TEXT  

Efficacy of methylprednisolone pulse therapy on neuroleptic malignant syndrome in Parkinson's disease
Sato et al.
J. Neurol. Neurosurg. Psychiatry 2003;74:574-576.
ABSTRACT | FULL TEXT  

Olanzapine Usage Associated With Neuroleptic Malignant Syndrome
Philibert et al.
Psychosomatics 2001;42:528-529.
FULL TEXT  

Neuroleptic malignant syndrome
Adnet et al.
Br J Anaesth 2000;85:129-135.
FULL TEXT  

Neuroleptic Malignant Syndrome in an Adolescent Head Trauma Patient
Trasmonte et al.
CLIN PEDIATR 1999;38:611-613.
 

Acute basagranTM poisoning mimicking neuroleptic malignant syndrome
Lin et al.
Hum Exp Toxicol 1999;18:493-494.
ABSTRACT  

Neuroleptic Malignant Syndrome: A Review
Pelonero et al.
Psychiatr. Serv. 1998;49:1163-1172.
ABSTRACT | FULL TEXT